Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation
L. Axt,A. Naumann,J. Toennies,S. P. Haen,W. Vogel,D. Schneidawind,S. Wirths,R. Moehle,C. Faul,L. Kanz,S. Axt,W. A. Bethge
DOI: https://doi.org/10.1038/s41409-019-0544-y
2019-05-14
Bone Marrow Transplantation
Abstract:Acute and chronic graft-vs.-host disease (aGvHD and cGvHD) are major complications after allogeneic hematopoietic cell transplantation (HCT) leading to substantial morbidity and mortality. This retrospective single-center study analyzes incidence, therapy, and outcome of GvHD in <i>n</i> = 721 patients ≥18 years having received allogeneic HCT 2004–2013 with a special focus on steroid refractory GvHD. Acute (<i>n</i> = 355/49.2%) and chronic (<i>n</i> = 269/37.3%) GvHD were mainly treated by steroids in first-line therapy. The proportion of steroid refractory aGvHD and cGvHD was 35.7% and 31.4%, respectively. As there is no standard therapy for steroid refractory GvHD, a range of different agents was used. In aGvHD, the overall response rate (ORR) of steroid refractory GvHD to second-line treatment was 27.4%. Mycophenolate mofetil (MMF) and mTOR inhibitors led to superior response rates (ORR 50.0% and 53.3%, respectively). In steroid refractory cGvHD therapy, ORR was 44.4%. Use of calcineurin inhibitors (CNI; <i>n</i> = 11/45.5%), MMF (<i>n</i> = 18/50.0%), mTOR inhibitors (<i>n</i> = 10/60.0%), and extracorporeal photophoresis (ECP; <i>n</i> = 16/56.3%) showed ORR above average. Targeted therapies lead to responses in 7.7% (<i>n</i> = 13). This data may help to improve the design of future prospective clinical studies in GvHD.
oncology,immunology,hematology,transplantation